Albert Clifford Morson
Albert Clifford Morson (1903–1979) was a British pathologist known for his significant contributions to the field of gastroenterology. He was a pioneer in the study of colorectal cancer and inflammatory bowel disease, and his work has had a lasting impact on the understanding and treatment of these conditions.
Early Life and Education[edit | edit source]
Albert Clifford Morson was born in 1903 in London, England. He attended University College London, where he studied medicine. After graduating, he trained in pathology at the Middlesex Hospital, where he developed a keen interest in gastrointestinal pathology.
Career[edit | edit source]
In 1932, Morson was appointed as a pathologist at the St Mark's Hospital, a specialist hospital for colorectal diseases. Here, he established a close working relationship with surgeon Cuthbert Dukes, and together they made significant contributions to the understanding of colorectal cancer.
Morson's work at St Mark's Hospital led to the development of the Dukes staging system for colorectal cancer, which is still widely used today. He also made significant contributions to the understanding of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
In addition to his clinical work, Morson was a prolific writer and researcher. He authored numerous scientific papers and textbooks, including the seminal work "Pathology of the Gastro-Intestinal Tract", which remains a key reference in the field.
Legacy[edit | edit source]
Albert Clifford Morson's work has had a lasting impact on the field of gastroenterology. His contributions to the understanding and treatment of colorectal cancer and inflammatory bowel disease have saved countless lives and continue to guide clinical practice today.
References[edit | edit source]
See also[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD